These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 36054016)

  • 21. Durability of Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Booster Vaccine Protection Against Omicron Among Healthcare Workers With a Vaccine Mandate.
    Richterman A; Behrman A; Brennan PJ; O'Donnell JA; Snider CK; Chaiyachati KH
    Clin Infect Dis; 2023 Feb; 76(3):e319-e326. PubMed ID: 35666508
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Real-world COVID-19 vaccine effectiveness against the Omicron BA.2 variant in a SARS-CoV-2 infection-naive population.
    Lau JJ; Cheng SMS; Leung K; Lee CK; Hachim A; Tsang LCH; Yam KWH; Chaothai S; Kwan KKH; Chai ZYH; Lo THK; Mori M; Wu C; Valkenburg SA; Amarasinghe GK; Lau EHY; Hui DSC; Leung GM; Peiris M; Wu JT
    Nat Med; 2023 Feb; 29(2):348-357. PubMed ID: 36652990
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative effectiveness and safety of BNT162b2 and CoronaVac in Hong Kong: A target trial emulation.
    Wan EYF; Wang B; Lee AL; Zhou J; Chui CSL; Lai FTT; Li X; Wong CKH; Hung IFN; Lau CS; Chan EWY; Wong ICK
    Int J Infect Dis; 2024 Sep; 146():107149. PubMed ID: 38909928
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk of glomerular diseases, proteinuria and hematuria following mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines.
    Cheng FWT; Wong CKH; Qin SX; Chui CSL; Lai FTT; Li X; Wan EYF; Chan EW; Au CH; Ye X; Tang SCW; Wong ICK
    Nephrol Dial Transplant; 2023 Jan; 38(1):129-137. PubMed ID: 36367015
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and immunogenicity of 3 doses of BNT162b2 and CoronaVac in children and adults with inborn errors of immunity.
    Leung D; Mu X; Duque JSR; Cheng SMS; Wang M; Zhang W; Zhang Y; Tam IYS; Lee TSS; Lam JHY; Chan SM; Cheang CH; Chung Y; Wong HHW; Lee AMT; Li WY; Chaothai S; Tsang LCH; Chua GT; Cheong KN; Au EYL; Kwok JSY; Chan KW; Chong PCY; Lee PPW; Ho MHK; Lee TL; Tu W; Peiris M; Lau YL
    Front Immunol; 2022; 13():982155. PubMed ID: 36203563
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effectiveness of BNT162b2 and CoronaVac in children and adolescents against SARS-CoV-2 infection during Omicron BA.2 wave in Hong Kong.
    Leung D; Rosa Duque JS; Yip KM; So HK; Wong WHS; Lau YL
    Commun Med (Lond); 2023 Jan; 3(1):3. PubMed ID: 36604522
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A comprehensive analysis of the efficacy and effectiveness of COVID-19 vaccines.
    He X; Su J; Ma Y; Zhang W; Tang S
    Front Immunol; 2022; 13():945930. PubMed ID: 36090988
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum Neutralization of SARS-CoV-2 Omicron BA.1 and BA.2 after BNT162b2 Booster Vaccination.
    Pedersen RM; Bang LL; Madsen LW; Sydenham TV; Johansen IS; Jensen TG; Justesen US; Andersen TE
    Emerg Infect Dis; 2022 Jun; 28(6):1274-1275. PubMed ID: 35356875
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Waning immune responses against SARS-CoV-2 variants of concern among vaccinees in Hong Kong.
    Peng Q; Zhou R; Wang Y; Zhao M; Liu N; Li S; Huang H; Yang D; Au KK; Wang H; Man K; Yuen KY; Chen Z
    EBioMedicine; 2022 Mar; 77():103904. PubMed ID: 35248996
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
    Costa Clemens SA; Weckx L; Clemens R; Almeida Mendes AV; Ramos Souza A; Silveira MBV; da Guarda SNF; de Nobrega MM; de Moraes Pinto MI; Gonzalez IGS; Salvador N; Franco MM; de Avila Mendonça RN; Queiroz Oliveira IS; de Freitas Souza BS; Fraga M; Aley P; Bibi S; Cantrell L; Dejnirattisai W; Liu X; Mongkolsapaya J; Supasa P; Screaton GR; Lambe T; Voysey M; Pollard AJ;
    Lancet; 2022 Feb; 399(10324):521-529. PubMed ID: 35074136
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety of Inactivated and mRNA COVID-19 Vaccination Among Patients Treated for Hypothyroidism: A Population-Based Cohort Study.
    Xiong X; Wong CKH; Au ICH; Lai FTT; Li X; Wan EYF; Chui CSL; Chan EWY; Cheng FWT; Lau KTK; Lee CH; Woo YC; Lui DTW; Wong ICK
    Thyroid; 2022 May; 32(5):505-514. PubMed ID: 35216517
    [No Abstract]   [Full Text] [Related]  

  • 32. Real-world effectiveness of homologous and heterologous BNT162b2, CoronaVac, and AZD1222 booster vaccination against Delta and Omicron SARS-CoV-2 infection.
    Suah JL; Tng BH; Tok PSK; Husin M; Thevananthan T; Peariasamy KM; Sivasampu S
    Emerg Microbes Infect; 2022 Dec; 11(1):1343-1345. PubMed ID: 35499301
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of the immunogenicity of BNT162b2 and CoronaVac COVID-19 vaccines in Hong Kong.
    Mok CKP; Cohen CA; Cheng SMS; Chen C; Kwok KO; Yiu K; Chan TO; Bull M; Ling KC; Dai Z; Ng SS; Lui GC; Wu C; Amarasinghe GK; Leung DW; Wong SYS; Valkenburg SA; Peiris M; Hui DS
    Respirology; 2022 Apr; 27(4):301-310. PubMed ID: 34820940
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunogenicity, Effectiveness, and Safety of Inactivated Virus (CoronaVac) Vaccine in a Two-Dose Primary Protocol and BNT162b2 Heterologous Booster in Brazil (Immunita-001): A One Year Period Follow Up Phase 4 Study.
    Grenfell RFQ; Almeida NBF; Filgueiras PS; Corsini CA; Gomes SVC; de Miranda DAP; Lourenço AJ; Martins-Filho OA; de Oliveira JG; Teixeira-Carvalho A; Campos GRF; Nogueira ML; Alves PA; Fernandes GR; Castilho LR; Lima TM; de Abreu DPB; Alvim RGF; Silva TBS; Jeremias WJ; Otta DA; Campi-Azevedo AC;
    Front Immunol; 2022; 13():918896. PubMed ID: 35757764
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Autoimmune conditions following mRNA (BNT162b2) and inactivated (CoronaVac) COVID-19 vaccination: A descriptive cohort study among 1.1 million vaccinated people in Hong Kong.
    Li X; Gao L; Tong X; Chan VKY; Chui CSL; Lai FTT; Wong CKH; Wan EYF; Chan EWY; Lau KK; Lau CS; Wong ICK
    J Autoimmun; 2022 Jun; 130():102830. PubMed ID: 35461018
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study.
    Jara A; Undurraga EA; Zubizarreta JR; González C; Pizarro A; Acevedo J; Leo K; Paredes F; Bralic T; Vergara V; Mosso M; Leon F; Parot I; Leighton P; Suárez P; Rios JC; García-Escorza H; Araos R
    Lancet Glob Health; 2022 Jun; 10(6):e798-e806. PubMed ID: 35472300
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk of acute liver injury following the mRNA (BNT162b2) and inactivated (CoronaVac) COVID-19 vaccines.
    Wong CKH; Mak LY; Au ICH; Lai FTT; Li X; Wan EYF; Chui CSL; Chan EWY; Cheng WY; Cheng FWT; Yuen MF; Wong ICK
    J Hepatol; 2022 Nov; 77(5):1339-1348. PubMed ID: 35817224
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dynamics of SARS-CoV-2 Antibody Response to CoronaVac followed by Booster Dose of BNT162b2 Vaccine.
    Fonseca MHG; Pinto ACMD; Silva MFS; de Melo ACL; Vasconcelos GS; Dos Santos ER; de Carvalho Araújo FM; de Andrade LOM
    Emerg Infect Dis; 2022 Jun; 28(6):1237-1240. PubMed ID: 35421324
    [TBL] [Abstract][Full Text] [Related]  

  • 39. COVID-19 vaccines versus pediatric hospitalization.
    Rosa Duque JS; Leung D; Yip KM; Lee DHL; So HK; Wong WHS; Lau YL
    Cell Rep Med; 2023 Feb; 4(2):100936. PubMed ID: 36801010
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Assessment of Heterologous and Homologous Boosting With Inactivated COVID-19 Vaccine at 3 Months Compared With Homologous Boosting of BNT162b2 at 6 Months.
    Low EV; Tok PSK; Husin M; Suah JL; Tng BH; Thevananthan T; Appannan MR; Yahaya H; Mohd Zin S; Muhamad Zin F; Sivasampu S; Peariasamy KM
    JAMA Netw Open; 2022 Aug; 5(8):e2226046. PubMed ID: 35947381
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.